CELG is also a good example in that most of their growth was while they were GIA. That stock went from $5-$10 to over $120 before it settled back down to $70 and was offered a BO at $90. If I’m not mistaken the market cap for CELG when it was as around $100/share was around $100 billion. The 2 differences I see between us and CELG is 1. CELG has more than 1 drug and 2. Vascepa is a much bigger blockbuster than anything CELG has.
GIA for the next 18-24 months, enjoy one hell of a price rise and then sell out for a nice premium. Not a bad outcome if you ask me, but long term GIA might be even better.
News 
Market Data 
Discover 
AI
